Go to Page # Page of 30

The Comprehensive Type 2 Diabetes Management Algorithm - 2018 Executive Summary

 Alan J. Garber MD PhD, Martin J. Abrahamson MD, Joshua I. Barzilay MD, Lawrence Blonde MD, Zachary T
  14th-Feb-2018
Description: This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience.
Views: 1553
Domain: Medical
Category: Therapy
Contributing Organization: AACE
 ‐ More of their Presentations
Contents:
AACE/ACE Consensus Statement
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF
CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF
ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES
MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY
Alan J. Garber, MD, PhD, FACE1; Martin J. Abrahamson, MD2; Joshua I. Barzilay, MD, FACE3;
Lawrence Blonde, MD, FACP, MACE4; Zachary T. Bloomgarden, MD, MACE5; Michael ... See more

Recent Presentations

Senhwa Biosciences, Inc

The information contained in this confidential document (“Presentation”) has been prepared by Senhwa Biosciences (the "Company"). It has not been fully verified and is subject to m

...
19 May, 2018
...
18 May, 2018

Real World Evidence: Sanofi's Strategy

The availability of real-world data (RWD) and the use of the appropriate analytical methods create a big opportunity to accelerate/increase patient access to innovative medicines.

...
17 May, 2018